title: Hormonal and surgical treatment of endometrial adenocarcinoma: actuarial survival.
abstract: We studied the survival period in two groups of patients with endometrial adenocarcinoma treated at the Chair B Institute of Gynecology and Obstetrics. The first series includes 30 of the 52 patients treated from 1976 to 1979. The second series includes 81 patients treated from 1980 to 1986. Lymph nodal positivity was present in 5 cases out of 30 patients belonging to Group I: all the interested lymph nodes were in the pelvic areas. Lymph nodal metastases were, instead, present in 10 cases as regard patients of Group II. Pelvic lymph nodes were involved in all the cases; in 5 of them also the paraaortic nodes were involved.
authors.affiliation: Department of Public Health, University of Turin, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Lanza
authors.forename: F
authors.initials: F
authors.lastname: D'Addato
authors.forename: A
authors.initials: A
authors.lastname: Re
authors.forename: L
authors.initials: L
authors.lastname: Zardo
authors.forename: P
authors.initials: P
authors.lastname: Vigezzi
authors.forename: M
authors.initials: M
authors.lastname: Raspollini
authors.forename: B
authors.initials: B
authors.lastname: Caldarola
authors.forename: G
authors.initials: G
authors.lastname: Rocca
authors.forename: D
authors.initials: D
authors.lastname: Proserpio
authors.forename: G
authors.initials: G
authors.lastname: Ferraris
mesh_terms: D019326:17-alpha-Hydroxyprogesterone; D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use; D011379:Prognosis; D014594:Uterine Neoplasms / Q000401:mortality / Q000628:therapy*
chemical_list: D006908:Hydroxyprogesterones; D019326:17-alpha-Hydroxyprogesterone